Butterfly Network

$Butterfly Network(BFLY.US)

Context: I entered BFLY at $4.65 before the stock’s major run. In June, Midjourney Medical unveiled a full-body imaging platform using Butterfly’s ultrasound-on-chip technology, sending BFLY sharply higher. I trimmed half at $6.99 during the initial surge. After the catalyst attracted more attention and the rally continued, I added part of the position back at $8.30 during the subsequent pullback. Strong Q2 results later supported the move, with revenue increasing 39% year-on-year, gross margin reaching 71%, and management raising its full-year outlook.

My trade: Still holding, currently up 58.7%. The first trim secured profit, while the later addition restored some exposure after the Midjourney announcement changed the market’s expectations for the company.

Takeaway: Taking profit during a sudden spike helped manage risk, but trimming half immediately left me chasing part of the position back higher. Next time, I would scale out in smaller stages when a meaningful catalyst may continue driving the stock.

$Butterfly Network(BFLY.US)

The Bigger Story Is Starting to Show Up

Butterfly Network is best known for turning ultrasound into a handheld, whole-body imaging device powered by its proprietary Ultrasound-on-Chip technology.

The problem it is solving is access. Traditional ultrasound machines can be expensive, bulky and limited to specialised departments. Butterfly’s platform is designed to make medical imaging more portable and available closer to the patient.

Its latest Q2 results suggest that the story is beginning to show up in the numbers. Revenue reached $32.6 million, up 39% year over year, driven by particularly strong US demand. Gross margin also improved to 71.4%, helped by higher-margin Butterfly Embedded licensing revenue.

This is important because Butterfly may be evolving beyond simply selling handheld scanners. Its technology can also be licensed into third-party medical devices, potentially giving the company a more scalable and profitable revenue stream.

Recent developments support that broader thesis. Butterfly expanded into Brazil, while Embedded partner Aleph Neuro demonstrated brain-imaging results using Butterfly’s chip platform.

The risks remain. Butterfly is still loss-making, cash burn matters, and strong post-earnings expectations can make the stock volatile. But compared with the June story, there is now more evidence that rising demand and Embedded licensing are beginning to strengthen both revenue growth and margins.

I’m still holding my remaining BFLY shares while watching whether this momentum continues through stronger Embedded revenue, international growth and improving profitability. The bigger Butterfly story may finally be moving from possibility to measurable progress.

$Butterfly Network(BFLY.US)

A Bigger Story

Butterfly Network has become one of my stronger portfolio movers, with the position now showing a major gain after the stock continued pushing higher.

What first made Butterfly interesting to me was its handheld ultrasound technology — a portable and software-driven approach to medical imaging.

The bigger surprise was its five-year co-development and licensing agreement with Midjourney. What makes this interesting is not just BFLY getting an AI-related partner, but Midjourney itself moving into a completely new area beyond image generation.

That gives BFLY a new layer to the story: ultrasound-on-chip, licensing revenue, embedded technology and possible AI imaging applications.

I trimmed some shares to lock in profit, while continuing to hold the rest as momentum kept building. In hindsight it may look early, but partial profit-taking is still part of managing a winning trade.

For me, BFLY is a good reminder that patience can pay when the company story improves before the market fully prices it in.

Sometimes the win is not about selling the exact top — it is about recognising a stronger story, taking some profit, and still letting the rest run.

🦋 In BFLY’s case, the butterfly did not just fly.

It found Midjourney and entered its AI era.

$Butterfly Network(BFLY.US)

BFLY’s latest results look encouraging to me. Revenue grew 25% year over year to $26.5 million, gross margin improved to 68.9%, and adjusted EBITDA loss narrowed compared with last year.

The company also reaffirmed its full-year 2026 revenue guidance of $117 million to $121 million.

What I like here is that the story is not only about AI headlines or FDA clearance anymore. The business is also showing signs of better execution, with stronger revenue, better margins, and improving losses. That makes the setup more interesting than a simple hype trade.

That said, BFLY is still loss-making, so I’m not treating this as a risk-free turnaround. For me, the key question is whether the company can keep growing while reducing cash burn. If it can, the market may start taking the portable ultrasound story more seriously.

$Butterfly Network(BFLY.US) is finally starting to get some attention again.

What makes this one interesting to me is that Butterfly recently received FDA clearance for an AI-powered ultrasound tool for pregnancy assessment, which adds another layer to its portable ultrasound story. The company says the tool can estimate gestational age in under two minutes and it was trained on more than 21 million ultrasound images.

There’s also been some improvement in the business itself. In Butterfly’s latest reported quarter, revenue rose 41% year over year to a record $31.5 million, the company generated positive net cash flow of $6.3 million, and it reported its lowest annual cash usage in company history.

For me, that makes BFLY more interesting than a pure hype move. It still looks like a volatile medtech name, but there are actual product and execution developments behind the story.